A

Agilent Technologies Inc

• Simply Wall St·11h ago

  How New Diagnostic Win and Patent Loss Will Impact Agilent Technologies (A) Investors

• Dow Jones·2d ago

  Agilent Price Target Cut to $140.00/Share From $160.00 by Evercore ISI Group

• Dow Jones·2d ago

  Agilent Is Maintained at Outperform by Evercore ISI Group

• Benzinga·2d ago

  Evercore ISI Group Maintains Outperform on Agilent Technologies, Lowers Price Target to $140

• Simply Wall St·4d ago

  Agilent Technologies (A) Valuation Check After New Cell Imaging And Cancer Diagnostic Milestones

• TipRanks·5d ago

  Agilent Announces Transition Plan for Chief Legal Officer

• Simply Wall St·6d ago

  Is It Time To Revisit Agilent Technologies (A) After Recent Share Price Weakness

• Seeking Alpha·6d ago

  Energy soars as the strongest S&P 500 sector in Q2

• Seeking Alpha·04/01 14:38

  Nike one of the most overvalued among footwear stocks

• TipRanks·04/01 12:07

  Agilent announces BioTek Cytation 9 cell imaging multimode reader

• Simply Wall St·03/31 14:07

  Is New Esophageal Cancer Keytruda Test Approval Reshaping The Investment Case For Agilent Technologies (A)?

• NASDAQ·03/27 15:30

  Why Is Agilent (A) Down 6.2% Since Last Earnings Report?

• Simply Wall St·03/27 12:14

  There's A Lot To Like About Agilent Technologies' (NYSE:A) Upcoming US$0.255 Dividend

• NASDAQ·03/26 12:34

  Agilent Announces Expanded Approval Of PD-L1 IHC 22C3 PharmDx In Esophageal Or GEJ Carcinoma

• Benzinga·03/26 12:05

  Agilent Technologies Receives FDA Approval For PD-L1 IHC 22C3 PharmDx Code SK006 As Companion Diagnostic To Aid In Identifying Patients With Esophageal Or Gastroesophageal Junction Carcinoma